In studies of 140 multiple sclerosis patients and controls, the researchers identified two blood-based metabolites as potential markers of the disease.
Qualified patients will have immediate access to IQuity's MS test, with expected access later to an IBD-IBS test, and a fibromyalgia test.
The test will now be offered along with another cell-based test to detect a number of diseases often misdiagnosed as multiple sclerosis.
Numares will use its technology to advance work by Oxford researchers to create a noninvasive test to better diagnose MS.
A Winthrop-University Hospital team showed that demethylated circulating cell-free DNA from dying oligodendrocytes is a biomarker for relapsing-remitting MS.